Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last4,961 to 4,980 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| H01: Medication vs Total H01: Medication + CABG: H01: Cardiac Procedure: Heart Transplant | 3 of 602 0 of 610 | 0.5 points -0.2 to 1.5 | 1,212 | NCT00023595 Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease |
| Total H01: Medication + CABG vs H01: Medication: H01: Cardiovascular Mortality (Defined as Sudden Death or Death Attributed to Recurrent MI, HF, a Cardiovascular Procedure, Stroke, or Other Cardiovascular Etiology). | 247 of 610 297 of 602 | -8.8 points -14.4 to -3.2 | 1,212 | NCT00023595 Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease |
| H01: Medication vs Total H01: Medication + CABG: H01: Heart Failure Hospitalization | 169 of 602 127 of 610 | 7.3 points 2.4 to 12.1 | 1,212 | NCT00023595 Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease |
| H01: Medication vs Total H01: Medication + CABG: H01: All-cause Mortality or Revascularization (CABG or PCI) | 478 of 602 388 of 610 | 15.8 points 10.7 to 20.7 | 1,212 | NCT00023595 Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease |
| H01: Medication vs Total H01: Medication + CABG: H01: All-cause Mortality or Heart-failure Hospitalization | 450 of 602 404 of 610 | 8.5 points 3.4 to 13.6 | 1,212 | NCT00023595 Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease |
| H01: Medication vs Total H01: Medication + CABG: H01: Cardiac Procedure: Heart Transplant | 4 of 602 1 of 610 | 0.5 points -0.4 to 1.5 | 1,212 | NCT00023595 Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease |
| H01: Medication vs Total H01: Medication + CABG: H01: Cardiac Procedure: Left Ventricular Assist Device (LVAD) | 2 of 602 4 of 610 | -0.3 points -1.4 to 0.6 | 1,212 | NCT00023595 Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease |
| Cervarix Group vs Engerix Group: Number of Subjects Reporting Medically Significant Conditions (MSCs) Including Potential Immune Mediated Diseases (pIMDs) | 5 of 606 7 of 606 | -0.3 points -1.6 to 0.9 | 1,212 | NCT01277042 Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years) |
| Cervarix Group vs Engerix Group: serious adverse events | 3 of 606 3 of 606 | 0.0 points -1.0 to 1.0 | 1,212 | NCT01277042 Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years) |
| CD5789 (Trifarotene) 50µg/g Cream vs Placebo Cream: serious adverse events | 2 of 602 4 of 610 | -0.3 points -1.4 to 0.6 | 1,212 | NCT02556788 Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris |
| V212 [Including High Antigen Lot] vs Placebo: deaths from any cause | 136 of 657 107 of 554 | 1.4 points -3.2 to 5.9 | 1,211 | NCT01229267 A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Participants Undergoing Hematopoietic Cell Transplants (HCTs) (V212-001) |
| V212 [Including High Antigen Lot] vs Placebo: serious adverse events | 420 of 657 374 of 554 | -3.6 points -8.9 to 1.8 | 1,211 | NCT01229267 A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Participants Undergoing Hematopoietic Cell Transplants (HCTs) (V212-001) |
| Best Practice Clinic-Based Care vs Telehealth Care: Number of Participants Identifying Clinic Visits as BP Care Burden at Six Months | 196 of 632 149 of 578 | 5.2 points 0.1 to 10.3 | 1,210 | NCT02996565 Pragmatic Trial Comparing Telehealth Care and Optimized Clinic-Based Care for Uncontrolled High Blood Pressure |
| Women 16-26 Years of Age vs Women 27-45 Years of Age: serious adverse events | 6 of 570 8 of 640 | -0.2 points -1.5 to 1.2 | 1,210 | NCT03158220 Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) |
| Aflibercept vs Placebo: serious adverse events | 331 of 611 184 of 598 | 23.4 points 17.9 to 28.7 | 1,209 | NCT00519285 Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer |
| CD5789 (Trifarotene) 50μg/g Cream vs Placebo Cream: Investigator Global Assessment (IGA) Success Rate at Week 12 | 180 of 612 116 of 596 | 9.9 points 5.1 to 14.7 | 1,208 | NCT02566369 Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris |
| CD5789 (Trifarotene) 50μg/g Cream vs Placebo Cream: serious adverse events | 4 of 612 2 of 596 | 0.3 points -0.6 to 1.4 | 1,208 | NCT02566369 Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris |
| CD5789 (Trifarotene) 50µg/g Cream vs Placebo Cream: Investigator Global Assessment (IGA) Score of 1 (Almost Clear) or 0 (Clear) | 255 of 598 157 of 609 | 16.9 points 11.5 to 22.1 | 1,207 | NCT02556788 Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris |
| H5N1 Adjuvanted Group vs H5N1 Un-adjuvanted Group: Number of Subjects With Serious Adverse Events (SAEs). | 7 of 961 0 of 245 | 0.7 points -0.9 to 1.5 | 1,206 | NCT00449670 Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults |
| H5N1 Adjuvanted Group vs H5N1 Un-adjuvanted Group: Number of Subjects With Any Unsolicited Adverse Events (AEs) | 308 of 961 75 of 245 | 1.4 points -5.2 to 7.7 | 1,206 | NCT00449670 Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults |
Code
curl "https://conductscience.org/api/comparisons/v1?page=249"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=249
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT00023595-bd1f5251",
"title": "H01: Medication vs Total H01: Medication + CABG: H01: Cardiac Procedure: Heart Transplant",
"summary": "3 of 602 against 0 of 610; risk difference 0.5 points, 95% interval -0.2 to 1.5; NCT00023595, Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",
"record": "/library/comparisons/NCT00023595-bd1f5251",
"nct_id": "NCT00023595",
"kind": "outcome",
"participants": 1212,
"risk_difference": {
"value": 0.0049833887043189366,
"lower": -0.002085475722215995,
"upper": 0.014548062023536262
},
"group_1": "3 of 602",
"group_2": "0 of 610",
"difference": "0.5 points",
"interval": "-0.2 to 1.5",
"trial_title": "Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease"
},
{
"id": "NCT00023595-bf4b7d98",
"title": "Total H01: Medication + CABG vs H01: Medication: H01: Cardiovascular Mortality (Defined as Sudden Death or Death Attributed to Recurrent MI, HF, a Cardiovascular Procedure, Stroke, or Other Cardiovascular Etiology).",
"summary": "247 of 610 against 297 of 602; risk difference -8.8 points, 95% interval -14.4 to -3.2; NCT00023595, Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease",
"record": "/library/comparisons/NCT00023595-bf4b7d98",
"nct_id": "NCT00023595",
"kind": "outcome",
"participants": 1212,
"risk_difference": {
"value": -0.0884374489406895,
"lower": -0.1436704333303432,
"upper": -0.03243379291546418
},
"group_1": "247 of 610",
"group_2": "297 of 602",
"difference": "-8.8 points",
"interval": "-14.4 to -3.2",
"trial_title": "Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=250",
"request_id": "PCRsbOkcfSyPFCH3"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
The conductscience.com catalog
One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.
Open Targets
One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.
Open Targets
One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.
ClinicalTrials.gov
One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.
Cellosaurus
One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.
PubMed and NLM's journal list
One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant